Recent	recent	O	O
preclinical	preclinical	O	O
and	and	O	O
clinical	clinical	O	O
studies	studies	O	O
with	with	O	O
the	the	O	O
thymidylate	thymidylate	B_chemical	O
synthase	synthase	I_chemical	O
inhibitor	inhibitor	O	O
N10-propargyl-5,8-dideazafolic	n10-propargyl-5,8-dideazafolic	B_chemical	O
acid	acid	I_chemical	O
(	(	O	O
CB	cb	O	O
3717).CB	3717).cb	O	O
3717	3717	O	O
,	,	O	O
N10-propargyl-5,8-dideazafolic	n10-propargyl-5,8-dideazafolic	B_chemical	O
acid	acid	I_chemical	O
,	,	O	O
is	is	O	O
a	a	O	O
tight-binding	tight-binding	O	O
inhibitor	inhibitor	O	O
of	of	O	O
thymidylate	thymidylate	B_chemical	O
synthase	synthase	I_chemical	O
(	(	O	O
TS	ts	O	O
)	)	O	O
whose	whose	O	O
cytotoxicity	cytotoxicity	O	O
is	is	O	O
mediated	mediated	O	O
solely	solely	O	O
through	through	O	O
the	the	O	O
inhibition	inhibition	O	O
of	of	O	O
this	this	O	O
enzyme	enzyme	O	O
.	.	O	O

Recent	recent	O	O
preclinical	preclinical	O	O
studies	studies	O	O
have	have	O	O
focused	focused	O	O
on	on	O	O
the	the	O	O
intracellular	intracellular	O	O
formation	formation	O	O
of	of	O	O
CB	cb	B_chemical	O
3717	3717	I_chemical	O
polyglutamates	polyglutamates	S_chemical	O
.	.	O	O

Following	following	O	O
a	a	O	O
12-hour	12-hour	O	O
exposure	exposure	O	O
of	of	O	O
L1210	l1210	O	O
cells	cells	O	O
to	to	O	O
50	50	O	O
microM	microm	O	O
[3H]CB	[3h]cb	O	O
3717	3717	O	O
,	,	O	O
30	30	O	O
%	%	O	O
of	of	O	O
the	the	O	O
extractable	extractable	O	O
radioactivity	radioactivity	O	O
could	could	O	O
be	be	O	O
accounted	accounted	O	O
for	for	O	O
as	as	O	O
CB	cb	B_chemical	O
3717	3717	I_chemical	O
tetra-	tetra-	O	O
and	and	O	O
pentaglutamate	pentaglutamate	S_chemical	O
,	,	O	O
as	as	O	O
determined	determined	O	O
by	by	O	O
high-pressure	high-pressure	O	O
liquid	liquid	O	O
chromatography	chromatography	O	O
(	(	O	O
HPLC	hplc	O	O
)	)	O	O
analyses	analyses	O	O
.	.	O	O

As	as	O	O
inhibitors	inhibitors	O	O
of	of	O	O
isolated	isolated	O	O
L1210	l1210	O	O
TS	ts	O	O
,	,	O	O
CB	cb	B_chemical	O
3717	3717	I_chemical	O
di-	di-	O	O
,	,	O	O
tri-	tri-	S_chemical	O
,	,	O	O
tetra-	tetra-	O	O
and	and	O	O
pentaglutamate	pentaglutamate	S_chemical	O
are	are	O	O
26-	26-	O	O
,	,	O	O
87-	87-	O	O
,	,	O	O
119-	119-	O	O
and	and	O	O
114-fold	114-fold	O	O
more	more	O	O
potent	potent	O	O
than	than	O	O
CB	cb	B_chemical	O
3717	3717	I_chemical	O
,	,	O	O
respectively	respectively	O	O
,	,	O	O
and	and	O	O
their	their	O	O
formation	formation	O	O
may	may	O	O
,	,	O	O
therefore	therefore	O	O
,	,	O	O
be	be	O	O
an	an	O	O
important	important	O	O
determinant	determinant	O	O
of	of	O	O
CB	cb	B_chemical	O
3717	3717	I_chemical	O
cytotoxicity	cytotoxicity	O	O
.	.	O	O

In	in	O	O
early	early	O	O
clinical	clinical	O	O
studies	studies	O	O
with	with	O	O
CB	cb	B_chemical	O
3717	3717	I_chemical	O
,	,	O	O
activity	activity	O	O
has	has	O	O
been	been	O	O
seen	seen	O	O
in	in	O	O
breast	breast	O	B_disease
cancer	cancer	O	S_disease
,	,	O	O
ovarian	ovarian	O	B_disease
cancer	cancer	O	S_disease
,	,	O	O
hepatoma	hepatoma	O	O
,	,	O	O
and	and	O	O
mesothelioma	mesothelioma	O	O
.	.	O	O

Toxicities	toxicities	O	S_disease
included	included	O	O
hepatotoxicity	hepatotoxicity	O	S_disease
,	,	O	O
malaise	malaise	O	O
,	,	O	O
and	and	O	O
dose-limiting	dose-limiting	O	O
nephrotoxicity	nephrotoxicity	O	S_disease
.	.	O	O

This	this	O	O
latter	latter	O	O
effect	effect	O	O
is	is	O	O
thought	thought	O	O
to	to	O	O
be	be	O	O
due	due	O	O
to	to	O	O
drug	drug	O	O
precipitation	precipitation	O	O
within	within	O	O
the	the	O	O
renal	renal	O	O
tubule	tubule	O	O
as	as	O	O
a	a	O	O
result	result	O	O
of	of	O	O
the	the	O	O
poor	poor	O	O
solubility	solubility	O	O
of	of	O	O
CB	cb	B_chemical	O
3717	3717	I_chemical	O
under	under	O	O
acidic	acidic	O	O
conditions	conditions	O	O
.	.	O	O

In	in	O	O
an	an	O	O
attempt	attempt	O	O
to	to	O	O
overcome	overcome	O	O
this	this	O	O
problem	problem	O	O
,	,	O	O
a	a	O	O
clinical	clinical	O	O
trial	trial	O	O
of	of	O	O
CB	cb	B_chemical	O
3717	3717	I_chemical	O
administered	administered	O	O
with	with	O	O
alkaline	alkaline	O	O
diuresis	diuresis	O	O
is	is	O	O
under	under	O	O
way	way	O	O
.	.	O	O

Preliminary	preliminary	O	O
results	results	O	O
at	at	O	O
400	400	O	O
and	and	O	O
500	500	O	O
mg/m2	mg/m2	O	O
suggest	suggest	O	O
that	that	O	O
a	a	O	O
reduction	reduction	O	O
in	in	O	O
nephrotoxicity	nephrotoxicity	O	S_disease
may	may	O	O
have	have	O	O
been	been	O	O
achieved	achieved	O	O
with	with	O	O
only	only	O	O
1	1	O	O
instance	instance	O	O
of	of	O	O
renal	renal	O	B_disease
toxicity	toxicity	O	S_disease
in	in	O	O
10	10	O	O
patients	patients	O	O
.	.	O	O

Hepatotoxicity	hepatotoxicity	O	S_disease
and	and	O	O
malaise	malaise	O	O
are	are	O	O
again	again	O	O
the	the	O	O
most	most	O	O
frequent	frequent	O	O
side	side	O	B_disease
effects	effects	O	I_disease
.	.	O	O

Evidence	evidence	O	O
of	of	O	O
antitumor	antitumor	O	O
activity	activity	O	O
has	has	O	O
been	been	O	O
seen	seen	O	O
in	in	O	O
3	3	O	O
patients	patients	O	O
.	.	O	O

Pharmacokinetic	pharmacokinetic	O	O
investigations	investigations	O	O
have	have	O	O
shown	shown	O	O
that	that	O	O
alkaline	alkaline	O	O
diuresis	diuresis	O	O
does	does	O	O
not	not	O	O
alter	alter	O	O
CB	cb	B_chemical	O
3717	3717	I_chemical	O
plasma	plasma	O	O
levels	levels	O	O
or	or	O	O
urinary	urinary	O	O
excretion	excretion	O	O
and	and	O	O
that	that	O	O
satisfactory	satisfactory	O	O
urinary	urinary	O	O
alkalinization	alkalinization	O	O
can	can	O	O
be	be	O	O
readily	readily	O	O
achieved	achieved	O	O
.	.	O	O

